{"id":390581,"date":"2018-09-23T00:00:00","date_gmt":"2018-09-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0008-2018-biopharma-biosimilars-current-treatment-nephrology-us-eu-2018\/"},"modified":"2026-03-31T10:47:56","modified_gmt":"2026-03-31T10:47:56","slug":"biosbi0008-2018-biopharma-biosimilars-current-treatment-nephrology-us-eu-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0008-2018-biopharma-biosimilars-current-treatment-nephrology-us-eu-2018\/","title":{"rendered":"Biosimilars | Current Treatment | Nephrology | US\/EU | 2018"},"content":{"rendered":"<p>Although <abbr title=\"erythropoiesis-stimulating agent\">ESA <\/abbr>biosimilars entered the European market a decade ago, their uptake varies from country to country, as well as by drug and manufacturer. While European nephrologists have been able to prescribe <abbr title=\"erythropoiesis-stimulating agent\">ESA<\/abbr>\u00a0biosimilars\u00a0to their <abbr title=\"chronic kidney disease\">CKD<\/abbr> patients for several years, the first\u00a0<abbr title=\"erythropoiesis-stimulating agent\">ESA<\/abbr>\u00a0biosimilar, Retacrit,\u00a0was approved in the United States only recently. With Retacrit\u00a0launching soon in the United States, and with new biosimilars expected to soon enter all markets, it is vital to understand why <abbr title=\"erythropoiesis-stimulating agent\">ESA<\/abbr> biosimilar uptake varies in Europe and how it might impact upcoming\u00a0biosimilar launches in the United States and Europe. We surveyed nephrologists from France, Germany, and the United States to learn about their experience, familiarity with, and attitudes toward current biosimilars; the drivers and barriers to biosimilars\u2019 uptake; and their expectations for novel biosimilars.<\/p>\n","protected":false},"template":"","class_list":["post-390581","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-biosimilars","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390581\/revisions"}],"predecessor-version":[{"id":393705,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390581\/revisions\/393705"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}